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Objective. Regulatory agencies require the assessment of cardiovascular (CV) safety for new type 2 diabetes (T2D) therapies through
CV outcome trials (CVOTs). However, patients included in CVOTs assessing sodium-glucose cotransporter-2 inhibitors (SGLT2i)
might not be representative of those seen in clinical practice. This study examined the proportion of patients that would have been
enrolled into three main SGLT2i CVOTs to determine whether these trials’ eligibility criteria can be applied to a real-world
Mediterranean T2D population. Methods. Cross-sectional, retrospective, cohort study of T2D patients registered in primary care
centres of the Catalan Institute of Health using medical records from a population database (SIDIAP) that includes
approximately 74% of the population in Catalonia (Spain). Eligibility criteria were according to those of three SGLT2i CVOTs:
EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), and DECLARE-TIMI 58 (dapagliflozin). Results. By the end
of 2016, the database included 373,185 patients with T2D with a mean age of 70 ± 12 years, 54.9% male, with a mean duration
of T2D of 9 ± 6 years, and a mean glycated haemoglobin (HbA1c) of 7:12% ± 1:32 (59% with HbA1c < 7%). Of these, 86,534
(23%) had established CV disease and 28% chronic renal failure (estimated glomerular filtration < 60ml/min/1:73m2). Among
all included patients, only 8.2% would have qualified for enrolment into the EMPA-REG OUTCOME trial, 29.6% into the
CANVAS program, and 38% into the DECLARE-TIMI 58 trial. The main limiting factors for inclusion would have been a
previous history of CV disease and the baseline HbA1c value. Conclusion. The external validity of the analysed CVOTs is clearly
limited when applying the same eligibility criteria to a T2D Mediterranean population.
1. Introduction
Patients with type 2 diabetes (T2D) have an increased risk
of renal and cardiovascular disease (CVD) and mortality
[1]. Therefore, improvement in cardiovascular (CV) health
is one of the main goals of diabetes management. While
tight good glycaemic control in T2D is associated with
reduced risk of microvascular disease [2, 3], the benefit
regarding macrovascular disease is less clear [4–6]. Indeed,
a meta-analysis combining the results of large-scale trials
showed that intensive glucose-lowering therapy was associ-
ated with a significant reduction in the overall incidence of
CV events and myocardial infarction compared to conven-
tional therapy (odds ratio (OR) 0.89, P = 0:001; OR 0.84,
P < 0:001, respectively) [7]. However, there was no differ-
ence in the incidence of CV mortality [7]. Both the US
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) require, for each new antidia-
betic therapy to treat T2D, to show a neutral or beneficial
effect in CV safety through the conduction of CV outcome
trials (CVOTs) [8, 9].
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are
a promising group of new drugs for the treatment of T2D
that act by preventing the reabsorption of glucose from the
proximal renal tubule in the kidney [10]. Additionally, they
have numerous pleiotropic effects such as reducing blood
plasma glucose, body weight, and blood pressure and induc-
ing natriuresis [10]. In the particular case of SGLT2i, recent
CVOTs have shown renal and CV benefits and further stud-
ies are ongoing [11–13]. However, one of the major issues of
randomised clinical trials (RCTs) is the external validity of
the results, that is, to what extent the overall average effect
of the treatment can be generalised to a particular group of
patients or clinical setting [14]. For instance, the external
validity can be challenged by the trial’s setting (e.g., differ-
ences between countries regarding the health care system,
disease management, or natural history of the disease), the
inclusion and exclusion criteria, or differences between the
protocol trial and routine clinical practice, among other
issues [14].
The results of the CVOTs of three SLGT2 inhibitors
available in Spain published to date are EMPA-REG OUT-
COME with empagliflozin [15], CANVAS with canagliflo-
zin [16], and DECLARE-TIMI 58 with dapagliflozin [17].
The EMPA-REG OUTCOME trial included only patients
with established CV disease (CVD), i.e., secondary preven-
tion [15]. The other two trials included secondary preven-
tion patients and also patients with CV risk factors who
have not yet developed CVD (primary prevention): with
≥1 CV risk factors in the DECLARE-TIMI 58 trial [17]
and with ≥2 CV risk factors in the CANVAS study [16].
Since the eligibility criteria varied among these SGLT2i
CVOTs, it was expected that the external validity of the
different studies might also differ; thus, the trial popula-
tion does not actually represent the general T2D popula-
tion. Indeed, the external validity of CVOTs regarding
SGLT2i has been assessed by two recently published stud-
ies using clinical routine data from the US and Northern
Europe [18, 19]. Both studies found large differences
between trials regarding the proportion of patients seen
in clinical practice that would have met entry criteria in
these CVOTs, with the DECLARE-TIMI 58 trial as the
most generalisable and applicable one. Moreover, the
results from the study conducted in Northern Europe were
consistent across all four included countries (i.e., Germany,
The Netherlands, Norway, and Sweden) [18]. However,
there is no published information from Southern Euro-
pean countries so far, although the distribution of CV risk
factors as well as the prevalence of CVD in patients with
diabetes differs across regions in Europe [20, 21]. Based
on these potential differences, we hypothesised that the
external validity of the CVOTs could be different when
the general T2D population is estimated in a Mediterra-
nean country.
The aim of the present study was to determine the pro-
portion of patients with T2D in primary care that would be
eligible for inclusion in the CVOTs of SLGT2i in the popula-
tion served by the Catalonian Health Institute in Catalonia, a
Mediterranean area in the northeast of Spain.
2. Materials and Methods
2.1. Design. This was a cross-sectional retrospective study of
the T2D population attended at primary care centres of Cat-
alonia, an autonomous region located in the northeast of
Spain, corresponding to 12% of the total Spanish population.
We compared the potential eligibility of patients to those
included in publications describing three completed SLGT2i
CVOTs [15–17].
The study was approved by the Ethics Committee of the
Primary Health Care University Research Institute (IDIAP)
Jordi Gol in accordance with the Spanish regulations on
observational studies. This retrospective study using anon-
ymised data did not require obtaining informed consent
from the patients.
2.2. Data Source. Data from patients were extracted from
the SIDIAP database, which contains anonymised longitu-
dinal patient information obtained from electronic clinical
records; it incorporates available information from 288
primary care teams of the Catalonian Health Institute
(ICS), which serves around 5.6 million people, 74% of
the total population in Catalonia. The SIDIAP includes
demographic, clinical, and pharmacy-invoicing data pro-
vided by the CatSalut general database, and it has already
been used for epidemiological research purposes and real-
world evidence [22–24].
2.3. Inclusion and Exclusion Criteria. The study population
consisted of patients aged 18 years or older with a diagno-
sis of T2D (International Classification of Diseases (ICD-
10) codes E11, E11.0-E11.9, E14, and E14.0-E14.9) as of
31 December 2016 (index date). We excluded patients
with a diagnosis of type 1 diabetes, gestational diabetes
mellitus, and any other type of diabetes. After this initial
selection, we applied the inclusion and exclusion criteria
from the CVOTs for the SGLT2i commercialised up to date
in Spain, namely, empagliflozin (EMPA-REG OUTCOME
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trial), canagliflozin (CANVAS trial), and dapagliflozin
(DECLARE-TIMI 58 trial) (Supplementary Table 1) [15–17].
2.4. Study Variables. The following variables from the
SIDIAP database at the end of December 2016 were analysed:
age and gender; duration of T2D; the most recent value (clos-
est to 31 December 2016) of glycated haemoglobin (HbA1c);
and presence of risk factors, including hypertension (ICD-10
codes I10 and I15, or systolic blood pressure ðSBPÞ ≥ 140
and/or diastolic blood pressure ðDBPÞ ≥ 90mmHg, or use of
antihypertensive medications), dyslipidemia (ICD-10 codes
E780 to E785, or LDL cholesterol ðLDLcÞ ≥ 160mg/dl, or
use of lipid-lowering drugs), smoking status, body mass
index (BMI), estimated glomerular filtration rate (eGFR)
using the Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) equation, albumin-to-creatinine ratio
(UACR), and history of CVD (stroke, peripheral artery dis-
ease, ischaemic heart disease, and heart failure) (Supplemen-
tary Table 2). Noninsulin antidiabetic drugs (NIADs) and
insulin-active electronic prescriptions on the index date
were also considered.
2.5. Statistical Analysis. The eligibility was determined by
dividing the number of patients fulfilling each of the CVOTs
key inclusion and exclusion criteria by the total T2D regis-
tered population. Data were summarised as mean (standard
deviation (SD)) or n (%).
3. Results
A total of 373,185 patients with T2D were registered in the
SIDIAP database as of 31December 2016 (Table 1). Themean
age was 70:1 ± 12:3 years, and 54.9% were male. The mean
T2D duration was 9:3 ± 6:2 years, and the mean HbA1c was
7:12% ± 1:32. More than half (59%) of the patients had good
glycaemic control (HbA1c ≤ 7%), about one-third (28%) had
chronic kidney disease (eGFR < 60ml/min/1:73m2), and 4%
had severe renal insufficiency (eGFR < 30ml/min/1:73m2).
Overall, 77% of patients (n = 286,651) did not have any
ICD-10 code of established CVD recorded, thus consid-
ered primary prevention cases; 23% (n = 86,534) had an
ICD-10 code of an established CVD, so they were con-
sidered secondary prevention cases. Patients with estab-
lished CVD were more often men, older, and with a
longer T2D duration and had more CV risk factors
(Table 1).
Applying the EMPA-REG OUTCOME eligibility cri-
teria, only 8.2% (n = 30,559) of the patients included in
the SIDIAP database would have qualified for entry in
the trial (Table 2), while 29.6% (n = 110,551) could have








Gender, male, n (%) 204,707 (54.9) 56,882 (65.7) 147,825 (51.6)
Age (years), mean (SD) 70.1 (12.3) 74.8 (10.5) 68.7 (12.5)
Current smokers, n (%) 52,744 (14.1) 11,058 (12.8) 41,686 (14.5)
BMI (kg/m2), n (%)
≥30 144,592 (44.9) 30,366 (40.3) 114,226 (46.4)
>45 3,905 (1.2) 521 (0.7) 3,384 (1.4)
Duration of diabetes (years),
mean (SD)
9.3 (6.2) 10.9 (6.7) 8.8 (6.0)
HbA1c (%)†, mean (SD) 7.12 (1.32) 7.16 (1.32) 7.10 (1.33)
HbA1c ≤ 7%, n (%) 194,751 (59.0) 43,664 (56.6) 151,087 (59.8)
Hypertension, n (%) 268,394 (71.9) 70,026 (80.9) 198,368 (69.2)
Dyslipidemia, n (%) 223,785 (60.0) 56,194 (64.9) 167,591 (58.5)
eGFR (ml/min/1.73m2)†, n (%)
≥60 241,958 (72) 45,598 (58) 196,360 (76)
30-60 80,978 (24) 27,651 (35) 53,327 (21)
<30 13,262 (4) 5,909 (7) 7,353 (3)
UACR ≥ 30mg/g, n (%) 51,429 (13.8) 17,126 (19.8) 34,303 (12.0)
T2D treatment, n (%)
No antidiabetic medication 68,681 (18.4) 12,178 (14.1) 56,503 (19.7)
NIAD monotherapy 138,615 (37.1) 28,582 (33.0) 110,033 (38.4)
NIADs in combination 86,508 (23.2) 18,557 (21.4) 67,951 (23.7)
Insulin±NIAD 79,381 (21.3) 27,217 (31.5) 52,164 (18.2)
BMI: body mass index; eGFR: estimated glomerular filtration rate; NIAD: noninsulin antidiabetic drug; SD: standard deviation; T2D: type 2 diabetes; UACR:
urine albumin-to-creatinine ratio; HbA1c: glycated haemoglobin. ∗Secondary prevention: patients with established cardiovascular disease (ICD-10 codes for
coronary heart disease, cerebrovascular disease, or peripheral arteriopathy). ∗∗Primary prevention: patients without any ICD-10 code for cardiovascular
disease. †There were 12% of missing data in the registration of HbA1c and 10% in the registration of eGFR.
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been enrolled in the CANVAS program (Table 3) and 38%
(n = 141,653) would have been eligible for the DECLARE-
TIMI 58 trial (Table 4). In Figure 1, these results are shown in
comparison to those reported by two studies conducted in
the US and Northern Europe [18, 19].
Compared with the characteristics of the patients
enrolled in the three studied CVOTs (Table 5), the main lim-
iting factors for inclusion would have been the absence of a
history of CVD and the value of HbA1c. Specifically, only
23% of patients in our T2D population had a preexisting
CVD and only 41% had HbA1c values ≥ 7%. Finally, chronic
renal failure (present in 28% of our T2D patients) was a
restrictive criterion in DECLARE, while in EMPAREG and
CANVAS, only patients with severe renal failure
(eGFR < 30ml/min/1:73m2) were excluded (4% in SIDIAP).
4. Discussion
In this population-based study using routine clinical data, we
estimated the proportion of patients with T2D that would
have been eligible for inclusion in the main CVOTs regarding
the use of SGLT2i in our environment (Catalonia, Spain). We
found that the DECLARE-TIMI 58 CVOT trial had the high-
est representativeness, covering 38% of the T2D patients in
our general T2D population, which is in line with previously
reported studies conducted in Northern Europe and the US
Table 2: Eligibility criteria for the EMPA-REG OUTCOME (empagliflozin) trial and number of patients in the SIDIAP database that would
have met criteria for enrolment.
Eligibility criteria in EMPA-REG OUTCOME trial Potentially eligible patients from the SIDIAP database (N = 373,185)
Inclusion criteria n (%)
Age ≥ 18 years 373,185 (100)
Preexisting CV event: CHD, angina, MI, stroke, and PAD 86,534 (23.2)
HbA1c level 7.0%-≤10.0% 33,270 (8.9)
Main exclusion criteria n (%)
eGFR < 30ml/min/1:73m2 2,488 (0.7)
BMI > 45 kg/m2 223 (0.06)
Total eligible, n (%) 30,559 (8.2)
CHD: coronary heart disease; CV: cardiovascular; eGFR: estimated glomerular filtration rate; MI: myocardial infarction; PAD: peripheral artery disease; HbA1c:
glycated haemoglobin; BMI: body mass index. All the percentages refer to the proportion from the total number of eligible subjects of the SIDIAP database
(n = 373,185).
Table 3: Eligibility criteria for the CANVAS program (canagliflozin) and number of patients in the SIDIAP database that would have met
criteria for enrolment.
Eligibility criteria in the CANVAS program
Potentially eligible patients from the SIDIAP
database (n = 373,185)
Inclusion criteria In PP, n (%) In SP, n (%)
Age:
≥50 years in PP 349,896 (93.8) —
≥30 years in SP — 372,764 (99.9)
Primary prevention cohort
≥50 years and ≥2 CVRF:
(i) T2D duration ≥10 years
(ii) Hypertension
(iii) Current smoker
(iv) Micro- or macroalbuminuria
(v) HDLc − <39mg/dl (1mmol/l)
189,969 (50.9) —
Secondary prevention cohort
≥30 years and history of CV events (CHD, angina, MI, stroke, and PAD) — 86,531 (23.2)
HbA1c: 7.0%-10.5% 83,537 (22.4) 34,320 (9.2)
Main exclusion criteria In PP, n (%) In SP, n (%)
eGFR < 30ml/min/1:73m2 4731 (1.27) 2575 (0.69)
Total eligible in PP and SP, n (%) 78,806 (21.1) 31,745 (8.5)
Total eligible, n (%) 110,551 (29.6)
CHD: coronary heart disease; CV: cardiovascular; CVRF: cardiovascular risk factors; eGFR: estimated glomerular filtration rate; MI: myocardial infarction; PP:
primary cardiovascular prevention; SP: secondary cardiovascular prevention; PAD: peripheral artery disease; T2D: type 2 diabetes; HbA1c: glycated
haemoglobin; HDLc: high-density lipoprotein cholesterol. All the percentages refer to the proportion from the total number of eligible subjects of the
SIDIAP database (n = 373,185).
4 Journal of Diabetes Research
[13, 17, 25]. This result is not surprising since the DECLARE-
TIMI 58 CVOT trial included similar proportions of patients
in primary CV prevention and secondary CV prevention
(59% and 41%, respectively) [17], which ensures the highest
representativeness. The CVOT with the lowest generalisabil-
ity was the EMPA-REG OUTCOME trial because it included
only secondary prevention patients [15]. However, if we only
take into account patients with cardiovascular disease as eli-
gible to enter into the trials, the resulting proportion would
have been similar among the three trials: 8.2% for the
EMPAREG, 8.5% for the CANVAS program, and 7.9% for
the DECLARE trial. Indeed, the main differences in the
design of the different CVOT trials that we included were
the enrolment of patients at high CV risk at baseline:
EMPA-REG OUTCOME included only patients with T2D
and established CV disease (i.e., secondary prevention), while
both the CANVAS and the DECLARE-TIMI 58 also
included primary prevention patients. In our real-world
T2D population, the main limiting factors for inclusion in
the different CVOTs analysed were the absence of a history
of CV disease (present in the 23% of the patients) and glycae-
mic control: only 41% of the patients had a HbA1c ≥ 7%
(entry criteria for the EMPA-REG OUTCOME and CAN-
VAS trials), and 65.3% were above 6.5% threshold (entry cri-
terion in the DECLARE-TIMI 58 study).
Concern regarding poor external validity (i.e., generalisa-
bility) of RCTs is largely known and has implications for the
use (or underuse) of treatments in routine clinical practice
[14, 26]. This topic has also been addressed in the past
regarding RCTs in the field of diabetes. For instance, in a pre-
vious literature review, the external validity of large trials
assessing the impact of glycaemic control on CVD in patients
with T2D was reported as limited when applied to a T2D
population-based cohort [27]. Another recent study evalu-
ated the population representativeness of 1691 registered
T2D trials [28] and found that in 51.4% of cases (and
53.1% of phase 2 and 3 interventional trials), the population
representativeness was <5%. Of note, and in line with our
results, the eligibility criterion that had the largest effect on
the population representativeness was HbA1c [28]. Finally,
the study showed that the greater the number of eligibility
criteria, the lower the representativeness was, and the authors
concluded that the low representativeness of T2D trials could
Table 4: Eligibility criteria for the DECLARE-TIMI 58 trial (dapagliflozin) and number of patients in the SIDIAP database that would have
met criteria for enrolment.
Eligibility in the DELCLARE-TIMI 58 trial
Potentially eligible patients from the SIDIAP
database (n = 373,185)
Inclusion criteria In PP, n (%) In SP, n (%)
Age:
(i) In PP: ≥55 years; ≥60 in women
(ii) In SP: ≥40











≥40 years and history of CV events (CHD, angina, MI, stroke, and PAD) — 86,468 (23.2)
HbA1c 6.5%-<12% 165,777 (44.4) 50,872 (13.6)
Main exclusion criteria In PP In SP
eGFR < 60ml/min/1:73m2 53,851 (14.4) 21,145 (5.7)
Total eligible in PP and SP, n (%) 111,926 (30) 29,727 (7.9)
Total eligible, n (%) 141,653 (38%)
CHD: coronary heart disease; CV: cardiovascular; CVRF: cardiovascular risk factors; eGFR: estimated glomerular filtration rate; MI: myocardial infarction;
PAD: peripheral artery disease; PP: primary cardiovascular prevention; SP: secondary cardiovascular prevention; HbA1c: glycated haemoglobin. All the












































Figure 1: Graphical representation of the representativeness of
patients in SGLT2i CVOTs when compared to the general type 2
diabetes population from four European countries, the US, and
the present Mediterranean population.
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be attributed to safety concerns when designing the study,
which may lead to overly restrictive eligibility criteria to pre-
vent adverse events [28].
Chronic renal failure was a restrictive criterion in
DECLARE, while EMPA-REG OUTCOME and CANVAS
trials only excluded patients with severe renal insufficiency
(<30ml/min/1.73m2), present in 4% of our population.
However, renal benefits of SGLT2i have been shown in differ-
ent studies and one meta-analysis [29], particularly in the
EMPA-REG OUTCOME and CANVAS trials [15, 16, 30–
32], although these results were from secondary outcomes.
New trials are ongoing with the primary renal endpoint (kid-
ney outcome trials) focusing on patients with T2D and estab-
lished chronic kidney disease (CKD) [33, 34]. The latest
recommendations from the 2018 ADA/EASD Consensus
Guidelines suggest to consider the use of a SGLT2i in patients
with T2D and CKD [35]. In fact, the FDA has recently
modified this limitation for patients with moderate renal
impairment (i.e., eGFR45 60ml/min/1.73m2) for dapagli-
flozin, as previously done with canagliflozin 100mg and
empagliflozin 10mg [36]. In summary, in the US, SGLT2i
are still not recommended when eGFR is less than
45ml/min/1.73m2 and remain contraindicated in patients
with severe renal impairment (eGFR < 30ml/min/1:73m2),
end-stage renal disease, or on dialysis [36]. Conversely, the
EMA has not yet modified the general restriction of eGFR
< 60ml/min/1:73m2. However, it is likely that recommen-
dations by drug agencies for SGLT2i in CKD will change in
the future after the publication of the results from the ongo-
ing kidney outcome trials (CREDENCE, DAPA-CKD, and
EMPAGLIFLOZIN RENAL) [37]. In addition, recent results
of the CREDENCE trial showed that the risk of kidney failure
and renal or CV mortality was 30% lower in the group of
patients receiving canagliflozin compared to placebo (HR
for the primary composite outcome of end-stage kidney
disease, doubling of serum creatinine, or renal or CV
death = 0:70; 95% CI, 0.59–0.82) [38]. All the patients
included in this trial had an eGFR between 30 and
90ml/min/1.73m2 and albuminuria, and in a subgroup
analysis, the renal benefit of canagliflozin was higher among
patients with eGFR between 45 and 60ml/min/1.73m2
(HR 0.52; 95% CI, 0.38–0.72) [38].
Indeed, a recent systematic review and trial-level meta-
analysis of SGLT2i CVOT trials concludes that SGLT2i
reduce the risk of worsening eGFR in a broad spectrum of
T2D patients [39]. Considering the facts mentioned above,
if SGLT2i were allowed to be prescribed to patients with
eGFR>30ml/min/1.73m2, the proportion of patients eligible
for inclusion in the DECLARE TIMI 58 in the SIDIAP data-
base would have increased.
The results of the present study show that the patterns of
external validity of SGLT2i CVOTs were limited, in line with
the studies conducted in Northern Europe or the US [18, 19].
However, the proportion of eligible patients would have been
less in our population than in Northern Europe for all three
trials but higher than that in the US for the CANVAS and
EMPAREG studies as shown in Figure 1. This could be
explained by differences in the prevalence of CVD between
regions and countries. Indeed, the prevalence of CVD is
higher in countries from the north of Europe than from the
south of Europe [21], but it is also probable that differences
in the prevalence of specific CV risk factors by country and
region have impacted our results. The low eligibility for
CANVAS and EMPA-REG OUTCOME in the US study is
striking, although the percentage of patients having CVD
was similar to ours (23.7 and 23%, respectively). One expla-
nation for this discordance could be related to the different
methodologies used in the US study, which is an estimation





CANVAS DECLARE-TIMI 58 General population (SIDIAP database)
Drug Empagliflozin Canagliflozin Dapagliflozin Empagliflozin/canagliflozin/dapagliflozin
Participants, n 7,020 10,142 17,160 373,185
Male (%) 71.5 64.2 62.6 54.9
Age (years), mean (SD) 63.1 (8.7) 63.3 (8.3) 63.9 (6.8) 70.1 (12.3)
Patients with established
CVD, n (%)
7,020 (>99) 6,656 (66) 6,974 (41)
EMPA-REG OUTCOME criteria:
86,534 (23.2)
CANVAS criteria: 86,531 (23.2)
DECLARE-TIMI 58 criteria: 86,468 (23.2)
CVRFs, n (%) — 3486 (34) 10,186 (59)
CANVAS criteria: 189,969 (50.9)
DECLARE-TIMI 58 criteria: 289,126 (77.5)
HbA1c (%), mean (SD) 8.1 (0.8) 8.2 (0.9) 8.3 (1.2) 7.12 (1.32)
eGFR (ml/min/1.73m2), n (%)
≥60 5,199 (74.1) 8,114 (79.9) 15,959 (92.6) 241,958 (72)
<60-30 1,819 (25.9) 2,028 (20.1) 1,201 (7.4) 80,978 (24)
<30 0 0 0 13,262 (4)
CVD: cardiovascular disease; CVRF: cardiovascular risk factors; eGFR: estimated glomerular filtration rate; SD: standard deviation; CVOTs: cardiovascular
outcome trials.
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based on data from two NHANES surveys. In this study, data
from 20,293 volunteer subjects, 2,395 of whom had T2D,
were extrapolated to 23,941,512 persons having T2D in the
US [19]. For instance, these patients were younger than in
the other databases: 59 years old in the US, 68 years in
the European study, and 70 years in our study. As a result,
the prevalence of CV risk factors was lower in our database
(13.6% in the US vs. 28%). Conversely, the prevalence of
CVD in the European study (43.7% in Germany, 34.8% in
The Netherlands, 31.4% in Sweden, and 25.1% in Norway)
was higher in our database (23%) and produced higher per-
centages of inclusion in the CANVAS and EMPA-REG
OUTCOME trials [18].
On the other hand, the applicability of SGLT2i is cer-
tainly much wider than the strict entry criteria of
CVOTs, as shown in several of studies and subanalyses
reporting the additional benefits of SGLT2i, particularly
in chronic kidney disease and heart failure [40]. For
instance, real-world evidence (RWE) studies have also
confirmed reductions in mortality (43% to 49%) and hos-
pitalization for heart failure (40% to 51%) in hundreds of
thousands of patients [40]. So far, the main RWE studies
published are CVD-Real, CVD-Real 2, EASEL, and
EMPRISE; these studies compared SGLT2i with other
antidiabetic drugs, especially against DPP-4 inhibitors
(CVD-Real 2 and EMPRISE). However, our study aimed
at determining how many patients from our Mediterra-
nean database would be eligible to enter in each CVOT,
but not the applicability of SGLT2i in the whole diabetic
population. Thus, even though we found a low percent-
age of patients that would have been enrolled in each
of the cardiovascular outcome trials, we should not dis-
miss the additional benefits of using SGLT2i in the whole
diabetic population in terms of heart failure benefit.
Hence, our results should be taken with caution and
should not drive the decision to prescribe or not an
SGLT2i in routine practice without considering all clinical
aspects and patient preferences. Finally, we should point
out that, at the time of deciding whether to prescribe
or not an SGLT2i, clinicians should also refer to the lat-
est available evidence and updated guidelines for T2DM
management [35, 41]. In this line, the 2018 Consensus
Report of the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes
(EASD) state that, in the presence of cardiovascular dis-
ease, empagliflozin or canagliflozin should be recom-
mended if HbA1c levels are above target, usually above
7% [35]. Moreover, the recently published 2019 ESC
Guidelines in collaboration with the EASD recommend
the use of SGLT2i in case of established cardiovascular
disease or in subjects at high or very high CV risk, with-
out establishing any specific threshold for HbA1c [41].
This study has some limitations. The main limitations
derive from its retrospective observational nature, which
are common to all similarly designed studies using real-
world databases. For instance, 12% and 10% of patients had
no available HbA1c or eGFR values during the evaluated
year, respectively. On the other hand, the strength of the
present study is that it involves real-world data from a Med-
iterranean region where the prevalence of CV risk factors and
CVD in patients with T2D is expected to be different from
that in Northern Europe or the US [21].
5. Conclusions
This study shows that there are considerable differences in
the external validity of the different CVOTs of SGLT2i when
applying the same eligibility criteria to the T2D population of
Catalonia. The DECLARE-TIMI 58 CVOT was the most
generalisable, while the EMPA-REG OUTCOME and CAN-
VAS trials were much less representative of real-world T2D
patients. However, the clinical applicability of SGLT2i in rou-
tine practice goes beyond the strict inclusion criteria of
CVOTs and it is important to consider all patient-centered
aspects before decision-making in T2D management.
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